Skip to main navigation
Skip to search
Skip to main content
Prince Sattam bin Abdulaziz University Home
Home
Profiles
Research units
Projects
Research output
Prizes
Activities
Search by expertise, name or affiliation
Hurdles to breakthrough in CAR T cell therapy of solid tumors
Faroogh Marofi
, Harun Achmad
, Dmitry Bokov
, Walid Kamal Abdelbasset
, Zeid Alsadoon
, Supat Chupradit
, Wanich Suksatan
, Siavash Shariatzadeh
, Zahra Hasanpoor
, Mahboubeh Yazdanifar
, Navid Shomali
, Farhad Motavalli Khiavi
Physical Therapy and Health Rehabilitation
Tabriz University of Medical Sciences
Universitas Hasanuddin
Sechenov First Moscow State Medical University
Biotechnology and Food Safety
The Islamic University, Najaf
Chiang Mai University
Chulabhorn Royal Academy
Shahid Beheshti University of Medical Sciences
Tarbiat Modarres University
Stanford University
Pasteur Institute of Iran
Research output
:
Contribution to journal
›
Review article
›
peer-review
42
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Hurdles to breakthrough in CAR T cell therapy of solid tumors'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Chimeric Antigen Receptor T-Cell Immunotherapy
100%
T Cell
100%
Solid Malignant Neoplasm
100%
Neoplasm
66%
Chimeric Antigen Receptor
66%
Malignant Neoplasm
33%
Tumor Microenvironment
33%
Monoclonal Antibody
33%
Hematologic Malignancy
33%
Tumor Antigen
33%
B Cell
33%
Immunosuppressive Drug
33%
Chimeric Antigen Receptor T-Cell
33%
Major Histocompatibility Complex
33%
Cytokine Release Syndrome
33%
Immunology and Microbiology
T Cell
100%
Chimeric Antigen Receptor T-Cell Therapy
100%
Chimeric Antigen Receptor
66%
B Cell
33%
Face
33%
Chimeric Antigen Receptor T-Cell
33%
Immunosuppressive Drug
33%
Monoclonal Antibody
33%
Tumor Antigen
33%
Major Histocompatibility Complex
33%
Cytokine Release Syndrome
33%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Chimeric Antigen Receptor
100%
Neoplasm
40%
Malignant Neoplasm
20%
Tumor Microenvironment
20%
Monoclonal Antibody
20%
Hematologic Malignancy
20%
Tumor Antigen
20%
Immunosuppressive Agent
20%